Navigation Links
Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease
Date:6/9/2011

BRUSSELS, June 9, 2011 /PRNewswire/ -- A post hoc analysis from the RECOVER study (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine Transdermal System) suggested that patients with Parkinson's disease who used Neupro® (rotigotine transdermal system) may experience improvements in key markers of mood/cognition, such as taking interest in surroundings and getting pleasure out of life.

Additional data presented from a one year open label follow-up of RECOVER supported the continuing benefits of rotigotine transdermal system on motor, sleep and nocturnal symptoms.

These data were presented at the 15th International Congress of Parkinson's disease and Movement disorders in Toronto, Canada (June 5-9, 2011).

Effects of rotigotine transdermal system on mood and anhedonia

A post hoc analysis of the RECOVER study suggested that rotigotine transdermal system may be associated with improvements compared with placebo on 4 of the 7 individual items in the mood/cognition domain of the Parkinson's Disease Non-Motor Symptom Scale (PDNMSS). These were loss of interest in surroundings (p<0.0001), loss of interest in doing things (p<0.0001), appearance of sadness or depression (p=0.005) and difficulty experiencing pleasure (p=0.0235).

"While further study is needed to confirm, this post hoc exploratory analysis from a randomized double blind placebo controlled study suggested beneficial effects of rotigotine transdermal system on markers of mood and anhedonia in Parkinson's disease," commented Professor K. Ray Chaudhuri, King's College Hospital, London, UK.

Continued effects of rotigotine transdermal system on motor function, sleep and nocturnal symptoms

In this open-label extension study the beneficial effects of rotigotine transdermal system on early morning motor function and sleep disturbances that were seen in the RECOVER study were maintained for a further year of tr
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 "Whether it,s our family, ... day." In a single sentence, Dr. ... officer at Pfizer,s Centers for Therapeutic Innovation ... fueling progress at America,s biopharmaceutical companies. ... with academia, patient foundations and the National Institutes of ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
(Date:3/26/2015)... NORTH CHARLESTON, S.C. , March 26, 2015 ... issues and were told by their existing PACS vendor ... Memorial Hospital (CMH) determined that they needed a ... Clinch Memorial Hospital selected Avreo interWORKS due to ... that carries modern meaningful use standards through to ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... CITY, Calif., Nov. 12, 2010 AcelRx Pharmaceuticals, Inc. announced ... S-1 with the U.S. Securities and Exchange Commission (SEC) relating ... common stock. All shares of the common stock to be ... Piper Jaffray & Co. is acting as sole ...
... FARMINGDALE, N.Y., Nov. 12, 2010 Misonix, Inc. (Nasdaq: ... the art, ultrasonic medical device technology, which worldwide is ... for the first fiscal quarter ending September 30, 2010. ... and Richard Zaremba, Senior VP and Chief Financial Officer, ...
Cached Medicine Technology:Misonix Reports First Quarter Fiscal 2011 Financial Results 2Misonix Reports First Quarter Fiscal 2011 Financial Results 3Misonix Reports First Quarter Fiscal 2011 Financial Results 4Misonix Reports First Quarter Fiscal 2011 Financial Results 5Misonix Reports First Quarter Fiscal 2011 Financial Results 6
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ), Canada’s ... medical cannabis as a treatment for patients has ... dedicated to providing access to safe medical marijuana ... searching for medical marijuana treatment in legal medical ... domain for Canada. , With the partnership ...
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In light ... (case number 1:15-cv-10429, U.S. District Court, District of Massachusetts; ... the Eastern District of Pennsylvania), the San Diego personal ... Helbock, A.P.C. are announcing that they are available to ... of women who were prescribed Zofran while pregnant and ...
(Date:3/26/2015)... Elfster.com, the top-rated Secret Santa generator, is proud ... capabilities to its leading Secret Santa list technology. A ... one creates of things to do before one dies, ... name. Nowadays many millennials are creating summer bucket ... , "We are greatly expanding our technology to new ...
Breaking Medicine News(10 mins):Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2Health News:Plans for Bucket List Generator - Just In Time for Summer - Announced by Elfster 2
... 9 ULURU Inc. (NYSE Alternext: ULU) today announced the ... the Company effective immediately. Following his resignation as Chief ... Director of the Company.Renaat Van den Hooff has been appointed ... President and Chief Executive Officer. Mr. Van de Hooff ...
... /PRNewswire/ -- SecureWorks(R), one of the ... with Columbian-based ETEK International to extend its security services ... One of South America,s leading security providers, ETEK will ... include, among others, Intrusion Prevention and Detection, Security and ...
... March 9 Based on its recent analysis ... Sullivan recognizes ValveXchange, Inc. with the 2009 North ... Year Award for developing the innovative ValveXchange Heart ... valve, the patented system promises to mitigate the ...
... March 9 ProteoTech Inc. announced today that ... Dr. Luke Esposito, Director of In Vitro Screening, ... Parkinson,s Diseases, to be held in Prague, Czech Republic, March ... Snow will give an oral presentation discussing promising results pertaining ...
... Tenn., March 9 Brookdale Senior Living Inc. ... Bill Sheriff, Chief Executive Officer, and Mark Ohlendorf, Co-President ... the Company at the Barclays Capital Global Healthcare Conference ... beginning at 4:15 p.m. Eastern Time.The presentation is being ...
... March 9 DURECT Corporation (Nasdaq: DRRX ... will be presenting at the Cowen and Company 29th ... a.m. EDT. The conference is being held at ... live audio webcast of the presentation will be available ...
Cached Medicine News:Health News:ULURU Inc. Announces Senior Management Change 2Health News:SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 3Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 4Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 5Health News:ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009 2Health News:DURECT to Participate in Cowen and Company Healthcare Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: